INKT MiNK Therapeutics Inc

$INKT Last night, as I sat rolling a couple fingers of Weller 12 year old against my palms, I thought about all the speculative stocks I had purchased over many, many years. My face was reflected in the powered-down computer screen in front of me, and seemed content...but weary. That look I mused, came from years of fighting on the market ropes, through raging seas and weathered hopes. Indeed...I am weary of waiting....wait, wait, wait....patience...and usually I wait some more, but almost always...nothing happens. The stock sits there like a tall ship with no wind...dead in the water. Still, once in a blue moon the wind picks up...the sails unfurl and fill...and the boat begins to gather speed. Hoping for a nice ride on the USS - INKT.

$INKT • The Clinical Head Start: Early observational data presented at the Military Health System Research Symposium already showed that the first treated patients were alive at Day 28, showed improved oxygenation, and were removed from ventilators. If the fully randomized data matches these early indicators, the upward move has a very strong baseline. (page 2).

$INKT OceanBeach...here is what AI says when comparing INKT's Agent 797 with RIGL's drug The Crucial Differences in Their Likelihood of Success 1. Definitive Failure vs. Active Development • Fostamatinib: While it had theoretical backing early in the pandemic, its high-level failure in a 400-patient Phase 3 trial published in JAMA Network Open has minimized the likelihood of it ever becoming an approved or recommended ARDS treatment. • agenT-797: Developed by MiNK Therapeutics (NASDAQ: INKT), this therapy is on an upward trajectory. Following successful exploratory trials published in Nature Communications, MiNK launched a randomized Phase 2 trial (Trial NCT07615010) evaluating the drug across severe pneumonia-induced ARDS. (Page 1)

$INKT comparatively to the market… inkt is holding for now relatively speaking. Wait and see this could be bikini bottom

$INKT $ICU How the hell should I know, you’re the one that’s been here 2 months of Sundays. You tell me. ————————-++++++♾️++++++——————-

$INKT I hope everyone is focused on risk / reward and fundamentals here. ST showing SP up big pre-market today … on a volume of 2 shares. Yeap, someone traded 2 shares, about $25, and moved the reported pre-market SP. Buy this one on future potential, LT outlook, no worries. 2 share trades … too funny.

$INKT the guy from agen inc. Will talk about agent t797 (minks product) … I’m thinking the stocks should correlate in price movement… that being said inkt is behind

$INKT Strange that both INKT & IBRX both had big premarket and early trading volume spikes yesterday Coincidence? Or is the cat out-of-the-bag?

$INKT Sorry, cash moving forward? QTRLy burn rate? ICU investor here. Been through our 1/250 and still believe that will be completely erased in the next 4-5 years. Is this ♾️ sign biotech about to ramble down that path? It looks strong here. TIA.